7/103 sources · 3 publishersUpdated Oct 9, 01:46 UTC
TRex Bio completes $116.7 million Nasdaq IPO at $14 per share
TRex Bio priced 8.3 million shares at $14 each, raising $116.7 million in its initial public offering. Trading of the newly listed shares began on Nasdaq on October 9, 2026 under the ticker TRXB. The underwriters received a 30‑day option to purchase an additional 1.25 million shares. Proceeds will fund the company’s clinical‑stage immunology pipeline.
Why it matters
The capital raise provides funding for TRex Bio’s pipeline, potentially advancing its regulatory T‑cell therapies. The IPO adds a new biotech stock to the market, giving investors a fresh equity opportunity.
Key facts
- 1TRex Bio priced 8.3 million shares at $14 each. tradingview.com
- 2The offering raised $116.7 million. tradingview.com
- 3Trading began on Nasdaq on October 9, 2026 under ticker TRXB. tradingview.com
- 4Underwriters have a 30‑day option to purchase an additional 1.25 million shares. tradingview.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.